Treatment Resistant Depression — Schema Therapy for Patients With Chronic Treatment Resistant Depression
Citation(s)
Barnhofer T, Brennan K, Crane C, Duggan D, Williams JM A comparison of vulnerability factors in patients with persistent and remitting lifetime symptom course of depression. J Affect Disord. 2014 Jan;152-154:155-61. doi: 10.1016/j.jad.2013.09.001. Epub 2013 Sep 20.
Demyttenaere K, Van Duppen Z The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol. 2019 Feb 1;22(2):85-92. doi: 10.1093/ijnp/pyy052.
Kohler S, Chrysanthou S, Guhn A, Sterzer P Differences between chronic and nonchronic depression: Systematic review and implications for treatment. Depress Anxiety. 2019 Jan;36(1):18-30. doi: 10.1002/da.22835. Epub 2018 Oct 9.
Licht RW, Qvitzau S, Allerup P, Bech P Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand. 2005 Feb;111(2):144-9. doi: 10.1111/j.1600-0447.2004.00440.x.
Lim CR, Barlas J The effects of Toxic Early Childhood Experiences on Depression according to Young Schema Model: A Scoping Review. J Affect Disord. 2019 Mar 1;246:1-13. doi: 10.1016/j.jad.2018.12.006. Epub 2018 Dec 10.
Ostergaard SD, Bech P, Miskowiak KW Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D(6)) as outcome measure. J Affect Disord. 2016 Jan 15;190:842-845. doi: 10.1016/j.jad.2014.10.047. Epub 2014 Nov 7.
Renner F, Arntz A, Peeters FP, Lobbestael J, Huibers MJ Schema therapy for chronic depression: Results of a multiple single case series. J Behav Ther Exp Psychiatry. 2016 Jun;51:66-73. doi: 10.1016/j.jbtep.2015.12.001. Epub 2015 Dec 8.
Renner F, Lobbestael J, Peeters F, Arntz A, Huibers M Early maladaptive schemas in depressed patients: stability and relation with depressive symptoms over the course of treatment. J Affect Disord. 2012 Feb;136(3):581-90. doi: 10.1016/j.jad.2011.10.027. Epub 2011 Nov 25.
Riso LP, Miyatake RK, Thase ME The search for determinants of chronic depression: a review of six factors. J Affect Disord. 2002 Jul;70(2):103-15. doi: 10.1016/s0165-0327(01)00376-7.
Timmerby N, Andersen JH, Sondergaard S, Ostergaard SD, Bech P A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psychosom. 2017;86(3):141-149. doi: 10.1159/000457131. Epub 2017 May 11.
Yakin D, Grasman R, Arntz A Schema modes as a common mechanism of change in personality pathology and functioning: Results from a randomized controlled trial. Behav Res Ther. 2020 Mar;126:103553. doi: 10.1016/j.brat.2020.103553. Epub 2020 Jan 16.
A Randomized Controlled Trial of Schema Therapy for Patients With Chronic Treatment Resistant Depression
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.